Response assessment
DISEASE, EVALUABLE, ACUTE MYELOID LEUKEMIA
Evaluable patients for response include all patients who had measurable disease present at baseline, began treatment, and had their disease re‐evaluated. Response was assessed by bone marrow aspirates and biopsies performed every 2 months (mandated at the end of Cycle 2, Cycle 4, and Cycle 6). The best responses were captured as overall responses at any time point. Response was evaluated based on modified response criteria by the International Working Group (IWG) recommendations for acute myeloid leukemia (Table 